Proud to review clinical evidence, ongoing trials and biological rationale for local ablative therapy in #oligomet#NSCLC with thought leaders @danielrgomez44 and @IyengarPuneeth. Looking forward to upcoming phase 3 trial results! https://t.co/Mq5tFYW0rl
Our new study on nasopharyngeal cancer (NPC): proton therapy with IMPT for localized NPC is associated with fewer acute toxicities compared to standard of care IMRT, with local control rate of 100% at 2 years. @imrtlee@AnnaLeeMDMPH@MSK_RadOnc
https://t.co/YvzYYQyx20